| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $ | – | |
Sells | $ | – |
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Over the last 12 months, insiders at Galecto, Inc. have bought $undefined and sold $undefined worth of Galecto, Inc. stock.
On average, over the past 5 years, insiders at Galecto, Inc. have bought $139,855 and sold $614,784 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $10,750 was made by Schambye Hans T. (Chief Executive Officer) on 2022‑03‑22.
| Increased Positions | 15 | +83.33% | 1M | +649.96% |
| Decreased Positions | 9 | -50% | 168,585 | -99.05% |
| New Positions | 12 | New | 1M | New |
| Sold Out Positions | 6 | Sold Out | 162,058 | Sold Out |
| Total Postitions | 24 | +33.33% | 1M | +550.91% |
| Novo Holdings A/S | $1,889.00 | 4.33% | 86,579 | -13,334 | -13.35% | 2025-09-30 |
| Connective Capital Management, Llc | $588.00 | 1.35% | 26,956 | +26,956 | New | 2025-09-30 |
| Two Sigma Investments, Lp | $443.00 | 1.02% | 20,296 | +20,296 | New | 2025-09-30 |
| Renaissance Technologies Llc | $328.00 | 0.75% | 15,044 | +500 | +3.44% | 2025-09-30 |
| Virtu Financial Llc | $286.00 | 0.66% | 13,128 | +13,128 | New | 2025-09-30 |
| Bank Of America Corp /De/ | $142.00 | 0.33% | 6,500 | +5,272 | +429.32% | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $31.00 | 0.07% | 1,427 | +485 | +51.49% | 2025-09-30 |
| Blackrock, Inc. | $2.00 | 0.01% | 100 | 0 | 0% | 2025-09-30 |
| Ubs Group Ag | $1.00 | <0.01% | 59 | -2,254 | -97.45% | 2025-09-30 |
| Barclays Plc | $1.00 | <0.01% | 55 | -45 | -45% | 2025-09-30 |